SVA Plumb Wealth Management LLC raised its position in Amgen, Inc. (NASDAQ:AMGN) by 7.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,428 shares of the medical research company’s stock after acquiring an additional 1,504 shares during the quarter. SVA Plumb Wealth Management LLC’s holdings in Amgen were worth $4,649,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of AMGN. FMR LLC lifted its stake in Amgen by 4.4% in the third quarter. FMR LLC now owns 35,823,268 shares of the medical research company’s stock worth $7,425,805,000 after acquiring an additional 1,505,266 shares during the last quarter. Natixis lifted its position in shares of Amgen by 2,612.1% during the 2nd quarter. Natixis now owns 529,816 shares of the medical research company’s stock worth $97,799,000 after buying an additional 510,281 shares during the last quarter. Candriam Luxembourg S.C.A. lifted its position in shares of Amgen by 54.8% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 1,075,050 shares of the medical research company’s stock worth $222,847,000 after buying an additional 380,562 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its position in shares of Amgen by 404.6% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 456,500 shares of the medical research company’s stock worth $94,333,000 after buying an additional 366,027 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Amgen by 17.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock worth $436,551,000 after buying an additional 343,690 shares during the last quarter. Institutional investors own 76.94% of the company’s stock.
Several brokerages have recently weighed in on AMGN. Jefferies Financial Group restated a “buy” rating and set a $220.00 price objective on shares of Amgen in a research report on Tuesday. Barclays restated a “neutral” rating and set a $195.00 price objective on shares of Amgen in a research report on Tuesday. Cantor Fitzgerald restated a “neutral” rating and set a $223.00 price objective on shares of Amgen in a research report on Tuesday. JPMorgan Chase & Co. set a $192.00 price objective on shares of Amgen and gave the stock a “neutral” rating in a research report on Tuesday. Finally, Royal Bank of Canada restated a “neutral” rating and set a $182.00 price objective on shares of Amgen in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Amgen presently has a consensus rating of “Hold” and an average price target of $205.68.
In other news, SVP Cynthia M. Patton sold 1,777 shares of Amgen stock in a transaction on Thursday, November 29th. The shares were sold at an average price of $202.88, for a total value of $360,517.76. Following the transaction, the senior vice president now directly owns 23,090 shares of the company’s stock, valued at approximately $4,684,499.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.19% of the company’s stock.
Shares of Amgen stock opened at $191.44 on Friday. The firm has a market capitalization of $126.81 billion, a PE ratio of 15.22, a price-to-earnings-growth ratio of 2.07 and a beta of 1.41. Amgen, Inc. has a 12 month low of $163.31 and a 12 month high of $210.19. The company has a debt-to-equity ratio of 2.05, a quick ratio of 2.84 and a current ratio of 3.08.
Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, October 30th. The medical research company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.45 by $0.24. The business had revenue of $5.90 billion for the quarter, compared to analysts’ expectations of $5.78 billion. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the company posted $3.27 EPS. As a group, equities research analysts expect that Amgen, Inc. will post 14.24 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be issued a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.03%. This is a boost from Amgen’s previous quarterly dividend of $1.32. Amgen’s payout ratio is presently 41.97%.
TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/12/08/sva-plumb-wealth-management-llc-purchases-1504-shares-of-amgen-inc-amgn.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Featured Article: Insider Trading – What You Need to Know
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.